ArticleJournal of personalized medicine2023
Omega-3 Fatty Acids Supplementation in the Treatment of Depression: An Observational Study.
Article in Journal of personalized medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 32 citations in OpenAlex.
- Review
- Omega-3 fatty acids as modulators of advanced glycation end products in aging: mechanistic pathways and clinical implications - a narrative review.Frontiers in aging · 2026Review
- From risk to resilience: a narrative overview of modifiable factors influencing depression in children with autism spectrum disorder (part I).Frontiers in psychiatry · 2026Review
- Review
- The dietary ligands, omega-3 fatty acid endocannabinoids and short-chain fatty acids prevent cytokine-induced reduction of human hippocampal neurogenesis and alter the expression of genes involved in neuroinflammation and neuroplasticity.Molecular psychiatry · 2025Article
- Molecular Crosstalk of Vitamin D3 with cGAS-STING and BDNF Pathways in a Rat Model of Chronic Stress.International journal of molecular sciences · 2025Article
- Systemic Inflammation at the Crossroad of Major Depressive Disorder and Comorbidities: A Narrative Review.International journal of molecular sciences · 2025Review
- A Study of Nutritional and Sensory Qualities of Pea Protein Isolate Beverages with a View to Their Potential Use in Patients with Psychiatric Disorders.Foods (Basel, Switzerland) · 2025Article
- Is Pilates effective in improving depressive disorders? A comprehensive overview.International clinical psychopharmacology · 2025Review
- Exploring Dietary Interventions in Autism Spectrum Disorder.Foods (Basel, Switzerland) · 2024Review
- Neutrophil-to-lymphocyte ratio as a predictive biomarker for early diagnosis of depression: A narrative review.Brain, behavior, & immunity - health · 2024Review
- Omega-3 Fatty Acids for Depression in the Elderly and Patients with Dementia: A Systematic Review and Meta-Analysis.Healthcare (Basel, Switzerland) · 2024Review
- Evaluation of Antidepressant Activity of Capsaicin Nanoemulsion in Nicotine Withdrawal-Induced Depression in Mice.Brain sciences · 2023Article
- Personalized Medicine of Omega-3 Fatty Acids in Depression Treatment in Obese and Metabolically Dysregulated Patients.Journal of personalized medicine · 2023Review
- Prevalence of Cognitive Decline in Type 2 Diabetes Mellitus Patients: A Real-World Cross-Sectional Study in Mysuru, India.Journal of personalized medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression is a common mood disorder characterized by persistent sadness and loss of interest. Research suggests an association between the inclusion of omega-3 fatty acids in the diet and a reduced risk for depression. The present study evaluated the effectiveness of omega-3 fatty acid supplements in alleviating depressive symptoms in patients with mild to moderate depression. A total of 165 patients suffering from mild to moderated depression were randomized to receive omega-3 fatty acid supplementation, an antidepressant (single agent), or a combination of an antidepressant and omega-3 fatty acid supplementation. The clinical features of depression were assessed using the Hamilton Depression Rating Scale (HDRS) during the follow-up period. A statistically significant improvement in depressive symptoms was observed from baseline to first, second and third follow-ups within each treatment arm as measured by HRDS scores (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.